ライフサイエンスコーパス: azathioprine

1 i.e. rituximab, belimumab, mycophenolate and azathioprine).

2 ent (116 to mycophenolate mofetil and 111 to azathioprine).

3 receiving infliximab,and 1 patient receiving azathioprine).

4 d lastly to both weekly adalimumab and daily azathioprine.

5 es within 2 weeks of starting treatment with azathioprine.

6 ond-line treatments such as methotrexate and azathioprine.

7 ne (6-TP) prodrugs include 6-thioguanine and azathioprine.

8 travenous cyclophosphamide and equivalent to azathioprine.

9 ethnicity, thrombocytopenia, and the use of azathioprine.

10 his effect can be negated by the addition of azathioprine.

11 its safety and tolerability in comparison to azathioprine.

12 hen compared with those receiving placebo or azathioprine.

13 tant treatment with mycophenolate mofetil or azathioprine.

14 plasma levels of cyclosporin A combined with azathioprine.

15 , especially in those who are not commencing azathioprine.

16 mission at month 28 with rituximab than with azathioprine.

17 gs were mycophenolate mofetil, sirolimus, or azathioprine.

18 th heterozygous range TPMT activity received azathioprine 1.0 mg/kg daily, compared with 2.5 mg/kg da

19 avenous injections of cyclophosphamide, oral azathioprine (1 to 3 mg per kilogram of body weight per

20 clophosphamide for 3 to 6 months followed by azathioprine (11 patients, the control group).

21 e-only group required immunosuppression with azathioprine (17% vs. 48%, P<0.001) or were hospitalized

22 nd 14 plus daily oral placebo capsules; oral azathioprine 2.5 mg/kg daily plus placebo infusions on t

23 mycophenolate mofetil (2 g per day) and oral azathioprine (2 mg per kilogram of body weight per day),

24 ral combination of danazol (10-15 mg/kg) and azathioprine (2 mg/kg) was given to 18 of the 35 patient

25 ients were randomly assigned to groups given azathioprine (2.5 mg . kg(-1) . day(-1), n = 68) or plac

26 ers were randomly assigned to treatment with azathioprine (2.5 mg kg(-1) day(-1), n = 65) or conventi

27 Cyclosporine (66.4%), methotrexate (47.3%), azathioprine (30.9%), and anti-TNFs (30.9%) were the mos

28 lavulanate (21 of 96; 22%), diclofenac (6%), azathioprine (4%), infliximab (4%), and nitrofurantoin (

29 weeks of treatment, 30 patients treated with azathioprine (44.1%) and 23 given placebo (36.5%) were i

30 limited ANCA-associated vasculitis) received azathioprine (58 patients) or rituximab (57 patients).

31 The immunosuppressive agents, azathioprine, 6-mercaptopurine and cyclosporine A, are c

32 5 and on CIST (steroids and/or cyclosporine, azathioprine, 6-mercaptopurine, FK-506, methotrexate) we

33 corticosteroids (OR, 3.4; 95% CI, 1.8-6.2), azathioprine/6-mercaptopurine (OR, 3.1; 95% CI, 1.7-5.5)

34 ed 5-aminosalicylates and 24.6% discontinued azathioprine/6-mercaptopurine in early pregnancy.

35 e metabolism of their respective substrates, azathioprine/6-mercaptopurine, 5-fluorouracil and sulind

36 and all prescriptions for 5-aminosalicylates azathioprine/6-mercaptopurine, and corticosteroids were

37 lled trials (N = 39) comparing methotrexate, azathioprine/6-mercaptopurine, infliximab, adalimumab, c

38 Recent studies of azathioprine/6-mercaptopurine, nitroimidazole antibiotic

39 xposed or not exposed to 5-aminosalicylates, azathioprine/6-mercaptopurine, or corticosteroids during

40 costeroids, and 1.27 (95% CI, 0.48-3.39) for azathioprine/6-mercaptopurine.

41 d infliximab + azathioprine were superior to azathioprine/6-mercaptopurine: adalimumab (OR, 2.9; 95%

42 000; 95% CI, 4-24), 1 of 133 patients taking azathioprine (752 of 100,000; 95% CI, 205-1914), 1 of 14

43 s predicted to be therapeutic for IF/TA were azathioprine, a drug to prevent acute rejection in renal

44 Azathioprine, a purine antimetabolite immunosuppressant,

45 and was associated with immunosuppression by azathioprine, a thiopurine prodrug.

46 Azathioprine, a widely used immunosuppressant, is also u

47 of infliximab and azathioprine (infliximab + azathioprine), adalimumab, and vedolizumab were superior

48 ncer subgroups between users and nonusers of azathioprine, adjusting for propensity scores.

49 r a Sweetlike presentation in the setting of azathioprine administration is azathioprine hypersensiti

50 6-Mercaptopurine/azathioprine alone and the addition of 6-mercaptopurine/

51 lone(P =.017) and 23.7% (18 of 76) receiving azathioprine alone(P =.032).

52 The thiopurines azathioprine and 6-mercaptopurine (6-MP) are effective i

53 Azathioprine and 6-mercaptopurine are the standard maint

54 The thiopurines azathioprine and 6-mercaptopurine have been extensively

55 Studies of azathioprine and 6-mercaptopurine metabolites will make

56 The prodrugs azathioprine and 6-mercaptopurine, which are well-establ

57 of treatment, and total therapeutic dose of azathioprine and 6-MP.

58 inhibitor and statin, 378 (9.2%) were taking azathioprine and an angiotensin-converting enzyme inhibi

59 Azathioprine and corticosteroids were discussed as poten

60 t with immunosuppressants such as rituximab, azathioprine and cyclophosphamide resulted in a marked r

61 When the temporal association between azathioprine and diarrhea was identified, the drug was t

62 olone sodium succinate, plasma exchange, and azathioprine and has remained in remission.

63 Combination therapy with azathioprine and infliximab for ulcerative colitis has n

64 t risk of hepatotoxicity was associated with azathioprine and infliximab, but the actual number of ca

65 Azathioprine and its metabolite 6-mercaptopurine (6-MP)

66 e cyclophosphamide group and one each in the azathioprine and mycophenolate mofetil groups).

67 ng cyclosporine A, mycophenolate mofetil, or azathioprine and prednisone).

68 ttransplant immunosuppression was limited to azathioprine and prednisone, acute rejection episodes we

69 These findings demonstrate that azathioprine and related compounds could be potent antim

70 patients with active disease who have failed azathioprine and rituximab.

71 Among these, the immunosuppressant azathioprine and the fluoroquinolone antibiotics ciprofl

72 receive a three-drug regimen of prednisone, azathioprine, and acetylcysteine; acetylcysteine alone;

73 given triple immunosuppression (tacrolimus, azathioprine, and corticosteroids), which was continued

74 ed of thymoglobulin, maintenance prednisone, azathioprine, and CsA.

75 ions, such as corticosteroids, methotrexate, azathioprine, and cyclophosphamide.

76 g history (mesalamine 5-aminosalicylic acid, azathioprine, and folate).

77 evidence favors the use of corticosteroids, azathioprine, and mycophenolate mofetil in ocular myasth

78 A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely

79 fibrosis in a clinical trial of prednisone, azathioprine, and N-acetylcysteine underwent HRCT at stu

80 ps -- receiving a combination of prednisone, azathioprine, and NAC (combination therapy), NAC alone,

81 re treated with a combination of prednisone, azathioprine, and NAC, as compared with placebo.

82 steroids, vitamin D analogues, fluorouracil, azathioprine, and oral prednisolone with improved outcom

83 The combination of cyclosporine, azathioprine, and prednisolone demonstrated recurrence i

84 osuppressive regimen including cyclosporine, azathioprine, and prednisolone.

85 ed PML after treatment with corticosteroids, azathioprine, and rituximab.

86 one noting no increased risk of cancer with azathioprine, another suggesting that anti-tumor necrosi

87 cribed any ISDs (cyclosporine, methotrexate, azathioprine, anti-TNF drugs, or others).

88 enance therapy with mycophenolate mofetil or azathioprine appears to be more efficacious and safer th

89 overlap syndromes, whereas mycophenolate and azathioprine are also used for both skin and lung diseas

90 6-thioguanine ((S)G), 6-mercaptopurine, and azathioprine are effective anticancer agents with remark

91 k meta-analysis, adalimumab and infliximab + azathioprine are the most effective therapies for induct

92 ugs (i.e., thioguanine [TG], mercaptopurine, azathioprine) are commonly used for the treatment of can

93 immunosuppressants (e.g., cyclophosphamide, azathioprine) are eventually required in most cases.

94 6-thioguanine ((S)G), 6-mercaptopurine, and azathioprine, are widely employed anticancer agents and

95 ercaptopurine (MP), 6-thioguanine ((S)G) and azathioprine, are widely used for the treatment of many

96 Identifying azathioprine as a risk factor for AML/MDS suggests that

97 L/MDS suggests that discontinuing the use of azathioprine as an immunosuppressant might reduce the in

98 We believe the study of azathioprine as systemic monotherapy for atopic eczema h

99 e aimed to assess the safety and efficacy of azathioprine as systemic monotherapy for moderate-to-sev

100 Treatment with azathioprine as systemic monotherapy produces clinically

101 asured the effect of two immunosuppressants, azathioprine (AZA) and mycophenolate acid (MPA), on both

102 Azathioprine (AZA) and tissue necrosis factor-alpha-inhi

103 is associated with less acute rejection than azathioprine (AZA) early after kidney transplantation.

104 ferior to cyclophosphamide (CYC) followed by azathioprine (AZA) for remission-induction in severe ANC

105 s against acute rejection when compared with azathioprine (AZA) in heart and renal transplantation.

106 Azathioprine (AZA) is used to maintain remission in auto

107 We suggest that immunosuppression by azathioprine (Aza) may be one such treatment.

108 ontinuous mycophenolate mofetil (MMF) versus azathioprine (AZA) therapy and renal allograft function,

109 blood and tissue from CD patients receiving azathioprine (AZA) therapy, and posttreatment Vdelta2 T

110 nous (IV) cyclophosphamide (CYC) followed by azathioprine (AZA) treatment in pulmonary fibrosis in SS

111 ndomized, and controlled trial comparing CsA/azathioprine (Aza) versus Tac/MMF in 289 kidney transpla

112 proach includes the use of immunomodulators [azathioprine (AZA), or 6-mercaptopurine (6-MP)] and newe

113 ere withdrawn from a regimen of steroids and azathioprine (AZA).

114 odes after renal transplantation compared to azathioprine (Aza).

115 tion signal inhibitor everolimus compared to azathioprine (AZA).

116 and July 2002; and group III (193) was given azathioprine (AzA)/CsA/P between January 1993 and Decemb

117 A second-line treatment option is azathioprine, but efficacy is lower, and evidence is wea

118 Azathioprine can induce severe small-bowel villus atroph

119 Unlicensed treatments include methotrexate, azathioprine, ciclosporin, and subcutaneous terbutaline

120 a limited 60-day course of cyclosporin A and azathioprine combined with weekly i.v. infusions of low-

121 ncluding 6-thioguanine, 6-mercaptopurine and azathioprine, commonly used for immune suppression and f

122 t) improvement in mean disease activity with azathioprine compared with a 20% (6.6 unit) improvement

123 (49 of 78) of patients receiving infliximab/azathioprine, compared with 54.6% (42 of 77) receiving i

124 (31 of 78) of patients receiving infliximab/azathioprine,compared with 22.1% (17 of 77) receiving in

125 We therefore hypothesized that azathioprine could also inhibit Vav1 in pancreatic tumor

126 of four discharge regimens (cyclosporine and azathioprine [CYA+AZA], CYA and mycophenolate mofetil [M

127 Azathioprine, cyclophosphamide, and rituximab had the mo

128 xic immunosuppressive agents other than MTX (azathioprine, cyclosporine, and leflunomide) were also a

129 biopsies obtained before and 4 months after azathioprine discontinuation showed complete reversal of

130 RNA levels were determined before and after azathioprine discontinuation.

131 ) by using TPMT enzyme activity to establish azathioprine dose.

132 rst 4 weeks, all participants received lower azathioprine doses (0.5 and 1.0 mg/kg daily, respectivel

133 caps compiled prospective data files on the azathioprine dosing patterns of 180 adult renal transpla

134 receive corticosteroids and 6-mercaptopurine/azathioprine during elective bowel surgery.

135 allow clarification of the relation between azathioprine effectiveness and metabolite profiles in ot

136 oliferative therapy use at our center (early azathioprine era: 1990-2000 vs modern mycophenolate era:

137 ersely, nonbiologic combination therapy with azathioprine exhibited the highest DR owing to ADRs.

138 icantly increased risk of SCC in relation to azathioprine exposure (1.56, 95% confidence interval [CI

139 In a large population with primary AID, azathioprine exposure was associated with a 7-fold risk

140 e administered for 3 to 6 months followed by azathioprine for 12 to 15 months.

141 ycophenolate mofetil was less effective than azathioprine for maintaining disease remission.

142 olled trials using mycophenolate mofetil and azathioprine for maintenance therapy have been performed

143 e alone and the addition of 6-mercaptopurine/azathioprine for patients receiving corticosteroids was

144 mycophenolate mofetil is more effective than azathioprine for preventing relapses in AAV.

145 ly results suggest that MMF is equivalent to azathioprine for remission maintenance, although large r

146 nce--via oral delivery of cyclosporine A and azathioprine for two months at the time of initiation of

147 tudy found great success in transitioning to azathioprine from mycophenolate mofetil prior to pregnan

148 dverse events occurred in 14 patients in the azathioprine group (20.6%) and 7 in the placebo group (1

149 -mg group (7.6 percent, P<0.001) than in the azathioprine group (21.5 percent).

150 r relapse had occurred in 17 patients in the azathioprine group (29%) and in 3 patients in the rituxi

151 til group (42/76 patients) compared with the azathioprine group (30/80 patients), with an unadjusted

152 -mg group (30.4 percent, P=0.01) than in the azathioprine group (52.8 percent).

153 s, and cancer developed in 2 patients in the azathioprine group and 1 in the rituximab group.

154 Eight patients in the azathioprine group and 11 in the rituximab group had sev

155 adverse events; there were 44 events in the azathioprine group and 45 in the rituximab group.

156 events occurred in 33.3% of patients in the azathioprine group and in 23.5% of those in the mycophen

157 e adverse events in 13 patients (16%) in the azathioprine group and there were 8 severe adverse event

158 Two patients in the azathioprine group died (1 from sepsis and 1 from pancre

159 A larger percentage of patients in the azathioprine group had adverse events that led to study

160 core >220, showed lower relapse rates in the azathioprine group than in the placebo group (11.8% vs 3

161 her cumulative proportion of patients in the azathioprine group were free of perianal surgery than in

162 3-year follow-up period, 16 patients in the azathioprine group were switched to mercaptopurine or me

163 In the azathioprine group, a median 67% of trimesters were spen

164 53% of the patients in the cyclophosphamide-azathioprine group, had a complete remission by 6 months

165 e mofetil group and 32.4% (36 of 111) in the azathioprine group.

166 m the placebo group and seven (11%) from the azathioprine group.

167 ler in the two everolimus groups than in the azathioprine group.

168 antly higher in the 3.0-mg group than in the azathioprine group.

169 her in the two everolimus groups than in the azathioprine group.

170 was higher in the mycophenolate mofetil and azathioprine groups than in the cyclophosphamide group (

171 antly lower in the mycophenolate mofetil and azathioprine groups than in the cyclophosphamide group.

172 cocorticoid and cyclophosphamide followed by azathioprine, has improved the disease prognosis.

173 Although calcineurin inhibitors and azathioprine have been linked with posttransplant malign

174 ated with antimetabolites (mycophenolate and azathioprine) have a lower risk of PTLD than those witho

175 We report a case of azathioprine hypersensitivity syndrome and review the li

176 Histologically, both azathioprine hypersensitivity syndrome and Sweet syndrom

177 Azathioprine hypersensitivity syndrome can present clini

178 Azathioprine hypersensitivity syndrome seems to be a neu

179 he setting of azathioprine administration is azathioprine hypersensitivity syndrome.

180 %), cyclosporine in 98 patients (74.2%), and azathioprine in 65 patients (49.2%).

181 In addition, MMF was shown to be superior to azathioprine in decreasing the incidence of treatment fa

182 Mycophenolate mofetil was superior to azathioprine in maintaining a renal response to treatmen

183 uppression with cyclophosphamide followed by azathioprine in patients with severe (organ-threatening)

184 nd, clinical trial comparing everolimus with azathioprine in recipients of a first heart transplant.

185 eterozygous range TPMT activity responded to azathioprine in similar proportions to other participant

186 ls has implications for the long-term use of azathioprine in the management of inflammatory disorders

187 ory bowel disease (of whom, 5,197 (11%) used azathioprine) in Denmark from 1997 to 2008.

188 e support the contention that treatment with azathioprine increases the risk of SCC in OTRs.

189 tivity syndrome and review the literature on azathioprine-induced eruptions with features of Sweet sy

190 se (TPMT) polymorphism (a key determinant of azathioprine-induced myelotoxicity) by using TPMT enzyme

191 nfliximab, the combination of infliximab and azathioprine (infliximab + azathioprine), adalimumab, an

192 ment of cultured pancreatic tumor cells with azathioprine inhibited Vav1-dependent invasive cell migr

193 ethyltransferase deficiency does not predict azathioprine intolerance.

194 Azathioprine is commonly prescribed for autoimmune hepat

195 Budesonide in combination with azathioprine is effective frontline therapy, and therape

196 Budesonide in combination with azathioprine is effective frontline therapy.

197 th African American ethnicity and the use of azathioprine; it appears to exert an impact on damage bu

198 The antimetabolites, such as methotrexate, azathioprine, leflunomide, and mycophenolate, are often

199 r time after transplantation but higher with azathioprine maintenance therapy (IRR=1.35, 95% CI 1.03-

200 for individualizing thiopurine therapy (i.e. azathioprine, mercaptopurine, and thioguanine).

201 ks of treatment with infliximab monotherapy, azathioprine monotherapy, or the 2 drugs combined in tum

202 to significantly better mucosal healing than azathioprine monotherapy.

203 include the chemotherapies cyclophosphamide, azathioprine, mycophenolate mofetil, and methotrexate.

204 round treatment was evenly distributed among azathioprine, mycophenolate mofetil, and methotrexate.

205 h NMO and NMO spectrum disorder treated with azathioprine, mycophenolate, and/or rituximab at the May

206 The 10 cases were treated with azathioprine, mycophenolic acid, methotrexate, or inflix

207 A total of 156 patients were assigned to azathioprine (n = 80) or mycophenolate mofetil (n = 76)

208 te optimum topical therapy to treatment with azathioprine (n=42) or placebo (n=21) for 12 weeks.

209 n (ciclosporin microemulsion/corticosteroids/azathioprine, n=92) in children who had had liver transp

210 day(-1), n = 65) or conventional management (azathioprine only in cases of corticosteroid dependency,

211 e (IBD) activity among patients treated with azathioprine or 6-mercaptopurine (6-MP).

212 g the immunosuppressant and anticancer drugs azathioprine or 6-mercaptopurine contains 6-thioguanine

213 ived 50% of the standard dose of thiopurine (azathioprine or 6-mercaptopurine), and patients homozygo

214 nticancer and immunosuppressant thiopurines, azathioprine or 6-mercaptopurine, is associated with acu

215 4% of patients treated with the thiopurines azathioprine or mercaptopurine.

216 patients receive maintenance treatment with azathioprine or methotrexate, the relapse rate remains h

217 Treatment with azathioprine or mycophenolate did not affect PV or PI in

218 Cyclosporine was combined with azathioprine or mycophenolate in cases unresponsive to o

219 nce immunosuppression included cyclosporine, azathioprine or mycophenolate mofetil, and prednisone.

220 Maintenance therapy, often with azathioprine or mycophenolate mofetil, is required to co

221 Secondary immunosuppressants (azathioprine or mycophenolate) and steroids remained unc

222 for patients receiving weekly adalimumab and azathioprine or weekly adalimumab alone if failure crite

223 (OR, 2.5; 95% CrI, 1.4-4.6) and infliximab + azathioprine (OR, 2.6; 95% CrI, 1.3-6.0).

224 ab (OR, 1.6; 95% CrI, 1.0-2.5), infliximab + azathioprine (OR, 3.0; 95% CrI, 1.7-5.5) for maintenance

225 i-tumor necrosis factor agents, infliximab + azathioprine (OR, 3.1; 95% CrI, 1.4-7.7) and adalimumab

226 ion at week 26 of treatment with infliximab, azathioprine, or both.

227 ) than RTRs who used cyclosporine, steroids, azathioprine, or had Medicare (P<0.05).

228 aced by oral prednisolone with cyclosporine, azathioprine, or mycophenolate as steroid-sparing agents

229 = 0.001) and 65% (13/20) in patients taking azathioprine (p = 0.14).

230 ab (P = .295) and 36.8% (28 of 76) receiving azathioprine (P =.001).

231 n of chronic GVHD therapy (P < .001); use of azathioprine, particularly when combined with cyclospori

232 per day (211 patients), or 1.0 to 3.0 mg of azathioprine per kilogram of body weight per day (214 pa

233 ce therapy included mycophenolate mofetil or azathioprine plus glucocorticoids in combination with Gr

234 ): cyclophosphamide for 3 months followed by azathioprine plus oral prednisolone).

235 Protocol induction was with azathioprine, prednisolone, and cyclosporine or tacrolim

236 drug immunosuppressive regimen (cyclosporine+azathioprine+prednisone) affects the islet engraftment p

237 lacement was first accomplished in 1967 with azathioprine, prednisone, and antilymphoid globulin.

238 interval: 1.15, 1.74), whereas former use of azathioprine (rate ratio = 1.02, 95% confidence interval

239 Due to the potential for anaphylaxis with azathioprine rechallenge, a better term for a Sweetlike

240 Azathioprine reduced the relapse rate by 72.1% but had a

241 tarium, replacing the antimetabolite prodrug azathioprine, reports have associated certain forms of w

242 he selective proliferation of MMR-defective, azathioprine-resistant myeloid cells may contribute sign

243 s associated with drugs, such as dapsone and azathioprine, respectively.

244 monthly corticosteroid pulses (temporary) or azathioprine, respectively.

245 ignificant heterogeneity between studies for azathioprine risk estimates and the outcomes of SCC, BCC

246 We aimed to resolve the issue of azathioprine's carcinogenicity by conducting a systemati

247 mab, mycophenolate, and, to a lesser degree, azathioprine significantly reduces relapse rates in NMO

248 Azathioprine sodium use was observed more frequently in

249 ditioning cytoreduction with hydroxyurea and azathioprine starting at -45 days pretransplant, and flu

250 Patients were randomly assigned to azathioprine (starting at 2 mg/kg/d) or mycophenolate mo

251 However, the addition of azathioprine substantially reduced the risk of HCMV repl

252 ted with 6-thioguanine (6-TG, a DNA-embedded azathioprine surrogate), the fluoroquinolones ciprofloxa

253 ors before retransplantation, treatment with azathioprine, T cell-depleting antibodies, and delayed r

254 drawal due to adverse events was higher with azathioprine than with mycophenolate mofetil (39.6% vs.

255 The immunosuppressant azathioprine, the fluoroquinolone antibiotics and vemura

256 h severe chronic GVHD were also treated with azathioprine, the independent effects of these factors c

257 rative efficacy and safety of infliximab and azathioprine therapy alone or in combination for ulcerat

258 is the first reported case of LYG related to azathioprine therapy in Crohn disease.

259 an with colonic Crohn disease on maintenance azathioprine therapy presented with right upper quadrant

260 study of adults with Crohn's disease, early azathioprine therapy was no more effective than placebo

261 th inflammatory bowel diseases and long-term azathioprine therapy.

262 Azathioprine toxicities cannot be predicted.

263 The DNA of azathioprine-treated patients contains 6-thioguanine (6-

264 No significant associations between azathioprine treatment and BCC (0.96, 95% CI 0.66-1.40)

265 Furthermore, azathioprine treatment decreased metastasis in both xeno

266 dial effusion occurred with sirolimus versus azathioprine treatment in a cardiac transplantation tria

267 Azathioprine treatment was associated with increased CIM

268 Azathioprine treatment was discontinued resulting in res

269 e, higher lipoprotein(a) level, proteinuria, azathioprine treatment, and prednisone dose.

270 verall and other skin cancers in relation to azathioprine treatment.

271 l lines and tumors were largely resistant to azathioprine treatment.

272 ths 6, 12, and 18 after study entry or daily azathioprine until month 22.

273 In multivariable modeling, both azathioprine use (P=0.005 for the mean-mean model and P=

274 Data on azathioprine use was also collected.

275 -dependent analyses were performed, although azathioprine use was also found to be a contributing fac

276 Azathioprine use was associated with an increased risk o

277 In conclusion, azathioprine use was associated with an increased risk o

278 In subgroup analyses, azathioprine use was associated with increased risk of l

279 that prolonged immunosuppressive therapy and azathioprine use were also significant risk factors for

280 Disease duration, lymphocyte count, and azathioprine use were shown to be significant independen

281 enteritis-like syndrome has been ascribed to azathioprine use, but chronic diarrhea has not.

282 After adjusting for donor age and azathioprine use, homozygous TLR2 mutation (RR 5.20 [1.6

283 tment (within 6 months after diagnosis) with azathioprine versus conventional management of patients

284 ermore, nonbiologic combination therapy with azathioprine was associated with a higher DR owing to AD

285 Azathioprine was associated with a lower risk of myeloma

286 el villus atrophy and chronic diarrhea after azathioprine was initiated (50 mg/day).

287 in survival outcome occurred (Theme IV) when azathioprine was replaced by cyclosporine (1979), which

288 Generally, azathioprine was well tolerated, although two individual

289 The purine analogue azathioprine, well known for its function as an anti-inf

290 Mycophenolate and azathioprine were associated with a lower risk of PTLD (

291 lts, a European trial concluded that MMF and azathioprine were equivalent in the ability to prevent r

292 te to severe UC treated with infliximab plus azathioprine were more likely to achieve corticosteroid-

293 Adalimumab, infliximab, and infliximab + azathioprine were superior to azathioprine/6-mercaptopur

294 Adalimumab and infliximab + azathioprine were superior to certolizumab: adalimumab (

295 Some localized melanomas may result from azathioprine, which acts synergistically with UV radiati

296 olitis responded well to corticosteroids and azathioprine, which is supportive of their immune pathog

297 Mycophenolate mofetil was superior to azathioprine with respect to the primary end point, time

298 agnosis is on a low dose of prednisolone and azathioprine, with no signs of relapse.

299 lts from a clinical trial, administration of azathioprine within 6 months of diagnosis of CD was no m

300 ed after immunosuppression with steroids and azathioprine without administration of calcineurin inhib